Valuation check: 6534.TW's profit margin is 30.39%, above the sector sector average of 13.4%.
Get informed when a big investor buys or sells
+ FollowAs of Sep 2026
Trailing 12 months ending Sep 2026
As of the most recent data (September 2026), 6534.TW shows a profit margin of 30.39%. That compares with 24.87% in the prior-year period — up 22.2% year over year. That is above the sector sector average of 13.4%. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, 6534.TW's profit margin is now 30.39% (was 24.87%) — a 22.2% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether CH Biotech R&D , Ltd. is outperforming or lagging.
The its sector sector average profit margin is about 13.4%. CH Biotech R&D , Ltd. is at 30.39%, which is higher that average. That is roughly 126.8% above the sector mean. Use the comparison chart on this page to see how 6534.TW stacks up against individual peers as well.
That compares with 24.87% in the prior-year period — up 22.2% year over year. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare CH Biotech R&D , Ltd. with peers to see if the move is company-specific or sector-wide.
Besides this profit margin page, Stockcircle has CH Biotech R&D , Ltd.'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect profit margin (currently 30.39%) with ownership activity and broader fundamentals.